electroCore Announces Departure of Peter Cuneo from the Board of Directors and Elects Thomas J. Errico, MD as Chairman of the Board
electroCore (NASDAQ:ECOR), a bioelectronic medicine and wellness company, announced leadership changes in its Board of Directors. Peter Cuneo is departing from the Board but will continue as a strategic advisor, while Dr. Thomas J. Errico has been elected as the new Chairman of the Board, effective September 2, 2025.
Cuneo served as a Board member since 2020 and as Chairman since 2021, playing a crucial role in electroCore's turnaround. Dr. Errico, who co-founded electroCore and previously served as Chairman of the Nominating and Governance Committee, will now lead the Board with his extensive experience in the company.
electroCore (NASDAQ:ECOR), azienda nel settore della medicina bioelettronica e del benessere, ha annunciato cambiamenti nella leadership del proprio Consiglio di Amministrazione. Peter Cuneo lascerà il Consiglio ma resterà consulente strategico, mentre Dr. Thomas J. Errico è stato eletto nuovo Presidente del Consiglio, con decorrenza 2 settembre 2025.
Cuneo faceva parte del Consiglio dal 2020 e ricopriva la carica di Presidente dal 2021, contribuendo in modo decisivo al rilancio di electroCore. Il Dr. Errico, cofondatore di electroCore e già Presidente del Comitato per la Nomina e la Governance, guiderà ora il Consiglio mettendo a frutto la sua lunga esperienza in azienda.
electroCore (NASDAQ:ECOR), compañía de medicina bioelectrónica y bienestar, anunció cambios en la dirección de su Junta Directiva. Peter Cuneo abandona la Junta pero permanecerá como asesor estratégico, mientras que Dr. Thomas J. Errico ha sido elegido nuevo Presidente de la Junta, con efecto a partir del 2 de septiembre de 2025.
Cuneo fue miembro de la Junta desde 2020 y presidente desde 2021, desempeñando un papel clave en la recuperación de electroCore. El Dr. Errico, cofundador de la compañía y anteriormente presidente del Comité de Nominaciones y Gobernanza, asumirá ahora la presidencia aportando su amplia experiencia en la empresa.
electroCore (NASDAQ:ECOR), 바이오일렉트로닉 의학 및 웰니스 기업이 이사회 구성의 변동을 발표했습니다. Peter Cuneo는 이사회에서 물러나지만 전략 고문으로는 계속 활동하며, Dr. Thomas J. Errico가 2025년 9월 2일부로 새로운 이사회 의장으로 선출되었습니다.
Cuneo는 2020년부터 이사회 멤버로 활동했으며 2021년부터 의장을 맡아 electroCore의 재도약에 핵심적인 역할을 했습니다. 공동 창업자이자 이전에 지명 및 거버넌스 위원회 의장을 맡았던 Errico 박사가 이제 회사에서의 풍부한 경험을 바탕으로 이사회를 이끌게 됩니다.
electroCore (NASDAQ:ECOR), société spécialisée en médecine bioélectronique et bien‑être, a annoncé des changements à la tête de son conseil d'administration. Peter Cuneo quitte le conseil mais restera conseiller stratégique, tandis que Dr. Thomas J. Errico a été élu nouveau président du conseil, à compter du 2 septembre 2025.
Cuneo siégeait au conseil depuis 2020 et en était le président depuis 2021, jouant un rôle déterminant dans le redressement d'electroCore. Le Dr Errico, cofondateur d'electroCore et ancien président du comité de nomination et de gouvernance, prendra désormais la tête du conseil en s'appuyant sur sa vaste expérience au sein de l'entreprise.
electroCore (NASDAQ:ECOR), ein Unternehmen für bioelektronische Medizin und Wellness, hat Änderungen in der Leitung seines Verwaltungsrats bekanntgegeben. Peter Cuneo scheidet aus dem Vorstand aus, bleibt jedoch als strategischer Berater tätig. Dr. Thomas J. Errico wurde zum neuen Vorstandsvorsitzenden gewählt, wirksam ab dem 2. September 2025.
Cuneo war seit 2020 Vorstandsmitglied und seit 2021 Vorsitzender und spielte eine zentrale Rolle bei der Wende von electroCore. Dr. Errico, Mitgründer von electroCore und zuvor Vorsitzender des Nominierungs- und Governance-Ausschusses, wird den Vorstand nun mit seiner umfassenden Erfahrung führen.
- None.
- Loss of experienced Chairman who led company turnaround
ROCKAWAY, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company.
“I want to offer my gratitude, and my congratulations to Peter Cuneo on his retirement from the electroCore Board of Directors,” commented Dan Goldberger, CEO of electroCore, Inc. “Peter has provided exceptional counsel to management and advocated strongly for all shareholders as a Board member since 2020 and as Chairman since 2021. His leadership and guidance during his tenure as Chairman was key in the turn-around of electroCore, and we wish him success as he continues to share his insights on leadership through his podcast, Superhero Leadership.”
“Dr. Errico co-founded electroCore and has been a consistent advocate for shareholders,” added Mr. Goldberger. “Dr. Errico’s counsel as the Chairman of the Nominating and Governance Committee has proven invaluable to both management and the board and I look forward to his leadership and continued stewardship as Chairman.”
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the anticipated contributions of new directors, the Company’s future business strategies, growth opportunities, prospects, product development, and market expansion, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to use strategic partnerships to provide more accessibility to those looking to purchase our consumer devices, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize its products, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
Who is the new Chairman of electroCore (NASDAQ:ECOR)?
Why did Peter Cuneo leave electroCore's Board of Directors?
What was Peter Cuneo's impact on electroCore (NASDAQ:ECOR)?
What is electroCore's (NASDAQ:ECOR) business focus?
